Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Participate in Two Investor Conferences in September
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Pricing of Initial Public Offering
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.